Literature DB >> 1729889

Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease.

E W Murray1, A R Giles, D Lillicrap.   

Abstract

The origin of new single-gene mutations resulting in inherited disease is an issue which may be at least partially resolved by our enhanced ability to detect these changes. In this report we describe the identification of a missense mutation at codon 553 (guanine to adenine) in the von Willebrand factor (vWf) gene in affected members of a family with type IIB von Willebrand's disease (vWd). We found no evidence for this substitution in 190 normal vWf genes. The encoded substitution of a methionine for a valine at this residue is nonconservative in nature and has affected a vWf protein region which has been shown to facilitate binding to the platelet receptor glycoprotein Ib. In patients with type IIB vWd this interaction is characteristically increased in affinity. This mutation has also recently been recorded in four other type IIB vWd families. Thus, there is strong circumstantial evidence to incriminate this substitution as the disease causing mutation in this family. As further supporting evidence for this claim, we have shown by vWf polymorphism analysis that the mutation originated in a vWf gene transmitted from a phenotypically normal grandfather. Analysis of the sperm from this individual showed that approximately 5% of the germ line contained the mutant 553 sequence. These results confirm (1) that the candidate type IIB vWd mutation in this family occurred at some time during the development of the germ line of the grandfather and presumably was related to a mitotic cell division and (2) that, as a result, he is a low-level germ-line mosaic for the mutation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1729889      PMCID: PMC1682529     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  48 in total

1.  Parameters affecting susceptibility of PCR contamination to UV inactivation.

Authors:  G Sarkar; S S Sommer
Journal:  Biotechniques       Date:  1991-05       Impact factor: 1.993

2.  Maternal duplication associated with gene deletion in sporadic hemophilia.

Authors:  J Gitschier
Journal:  Am J Hum Genet       Date:  1988-09       Impact factor: 11.025

3.  Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor.

Authors:  J Ware; J A Dent; H Azuma; M Sugimoto; P A Kyrle; A Yoshioka; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

4.  Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences.

Authors:  A M Randi; I Rabinowitz; D J Mancuso; P M Mannucci; J E Sadler
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

5.  Cosegregation of von Willebrand factor gene polymorphisms and possible germinal mosaicism in type IIB von Willebrand disease.

Authors:  E W Murray; A R Giles; P J Bridge; I R Peake; D P Lillicrap
Journal:  Blood       Date:  1991-04-01       Impact factor: 22.113

6.  Analysis of the relationship of von Willebrand disease (vWD) and hereditary hemorrhagic telangiectasia and identification of a potential type IIA vWD mutation (IIe865 to Thr).

Authors:  M C Iannuzzi; N Hidaka; M Boehnke; M E Bruck; W T Hanna; F S Collins; D Ginsburg
Journal:  Am J Hum Genet       Date:  1991-04       Impact factor: 11.025

7.  Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib.

Authors:  J P Girma; Y Takahashi; A Yoshioka; J Diaz; D Meyer
Journal:  Thromb Haemost       Date:  1990-10-22       Impact factor: 5.249

8.  A partial deletion of the muscular dystrophy gene transmitted twice by an unaffected male.

Authors:  B T Darras; U Francke
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

9.  Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction.

Authors:  D J Mancuso; E A Tuley; L A Westfield; T L Lester-Mancuso; M M Le Beau; J M Sorace; J E Sadler
Journal:  Biochemistry       Date:  1991-01-08       Impact factor: 3.162

10.  Somatic mosaicism and female-to-female transmission in a kindred with hemophilia B (factor IX deficiency).

Authors:  S A Taylor; K V Deugau; D P Lillicrap
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

View more
  5 in total

Review 1.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

2.  Seeming homozygosity in type-IIB von Willebrand's disease due to a polymorphism within the sequence of a commonly used primer.

Authors:  J C Eikenboom; P H Reitsma; E Briët
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

3.  Parental somatic and germ-line mosaicism for a multiexon deletion with unusual endpoints in a type III collagen (COL3A1) allele produces Ehlers-Danlos syndrome type IV in the heterozygous offspring.

Authors:  D M Milewicz; A M Witz; A C Smith; D K Manchester; G Waldstein; P H Byers
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

4.  De novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD.

Authors:  Ming-Ching Shen; Ming Chen; Gwo-Chin Ma; Shun-Ping Chang; Ching-Yeh Lin; Bo-Do Lin; Han-Ni Hsieh
Journal:  Thromb J       Date:  2016-10-04

5.  Ectopic expression of the RING domain of the Arabidopsis peroxin2 protein partially suppresses the phenotype of the photomorphogenic mutant de-etiolated1.

Authors:  Mintu Desai; Navneet Kaur; Jianping Hu
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.